<DOC>
	<DOCNO>NCT02565030</DOCNO>
	<brief_summary>This study help provide date prognostic data natural history untreated proximal CTEPH helpful discussion regard surgical versus medical treatment explore similarity difference distal CTEPH IPAH investigator hope get insight disease mechanisms patient distal CTEPH .</brief_summary>
	<brief_title>Chronic Thrombo-embolic Pulmonary Hypertension : Classification Long Term Outcome</brief_title>
	<detailed_description>Chronic thrombo-embolic pulmonary hypertension ( CTEPH ) think represent consequence failure thrombus resolution establishment thrombosis within elastic pulmonary artery . Thrombotic material becomes fibrosed , occlusive vascular remodel development secondary small vessel arteriopathy , term two-compartment model . This result increase pressure vascular resistance pulmonary vasculature lead eventually right heart failure . It demonstrate 2 year survival CTEPH patient mean pulmonary arterial pressure ( mPAP ) &gt; 50 mm Hg 20 % , however , preliminary data Sheffield Teaching Hospitals suggest survival significantly well . Until recently surgery treatment CTEPH select patient . Studies show 10 year survival patient CTEPH PEA surgery 74 % . More recently , patient inoperable CTEPH , drug therapy show improve exercise capacity . Despite recent publication natural history mechanism underlie CTEPH poorly understood . The main area research focus study improve understanding natural history chronic thromboembolic pulmonary hypertension . The purpose research protocol conduct retrospective review patient CTEPH diagnose Sheffield Centre 2001 2014 understand natural history disease include prognostic indicator . The Sheffield Service one large cohort CTEPH world ( &gt; 650 diagnose case since 2001 ) . Approximately half patient undergo curative surgery pulmonary endarterectomy . However , significant proportion patient operable disease decline surgery significant proportion patient disease distal surgery , call distal CTEPH . There relative paucity data ) natural history disease , ii ) understand relative contribution obstruction distal vasculopathy elevation pulmonary vascular resistance iii ) effect distal CTEPH right ventricular function iv ) distal CTEPH differs idiopathic pulmonary arterial hypertension ( IPAH ) . The second part study focus understand disease mechanism utilise MR image technique use Sheffield PH Biobank resource understand difference IPAH distal CTEPH cohort . The Sheffield PH Biobank sample detail phenotypic data 400 treatment na√Øve patient form pulmonary hypertension serial sampling long term follow provide unique resource make detailed comparison across form pulmonary hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>All patient diagnosis chronic thromboembolic pulmonary hypertension Idiopathic pulmonary arterial hypertension ( per European Society Cardiology guideline ) present Sheffield Pulmonary Vascular Disease Unit Royal Hallamshire Hospital 1st Jan 2001 1st Dec 2014 . Patients Pulmonary Hypertension cause pulmonary hypertension addition chronic thromboembolic pulmonary hypertension Idiopathic pulmonary arterial hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Distal Chronic thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Proximal Chronic thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Operable disease</keyword>
	<keyword>In-operable disease</keyword>
	<keyword>Pulmonary Endarterectomy</keyword>
	<keyword>PH specific target therapy</keyword>
	<keyword>Phosphodiesterase type 5 Inhibitors</keyword>
	<keyword>Endothelin Receptor Antagonist</keyword>
	<keyword>Prostacyclin analogue</keyword>
	<keyword>Soluble Guanylate cyclase stimulator</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>Bosentan</keyword>
	<keyword>Ambrisentan</keyword>
	<keyword>Macitentan</keyword>
	<keyword>Iloprost</keyword>
	<keyword>Riociguat</keyword>
	<keyword>Idiopathic Pulmonary Arterial Hypertension</keyword>
</DOC>